Axogen Announces Transition of Finance Team Leadership
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience primarily in the life sciences industry, he replaces Peter Mariani, who will depart Axogen following a brief transition period. The move aligns the executive team with the Company’s financial management and investor relations needs going forward as Axogen focuses on continued revenue growth across both business categories while driving toward being cash flow positive and profitable.
Related news for (AXGN)
- Axogen Announces Chief Financial Officer Transition
- Axogen, Inc. Reports 2025 First Quarter Financial Results
- Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
- axogen completes submission of biologics license application to u.s. food and drug administration for avance nerve graft®